Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Computed Tomography01:10

Computed Tomography

Tomography refers to imaging by sections. Computed tomography (CT) is a non-invasive imaging technique that uses computers to analyze several cross-sectional X-rays to reveal minute details about structures in the body.
The technique was invented in the 1970s and is based on the principle that as X-rays pass through the body, they are absorbed or reflected at different levels. In the technique, a patient lies on a motorized platform while a computerized axial tomography (CAT) scanner rotates...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

European urology focus·2026
Same author

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management?

European urology focus·2026
Same author

Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.

Translational oncology·2026

Related Experiment Video

Updated: May 31, 2026

Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging
08:04

Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging

Published on: April 14, 2011

Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system.

Jean-Mathieu Beauregard1, Michael S Hofman, Jucilene M Pereira

  • 1Molecular Imaging Research Group, Medical Imaging Department, Centre hospitalier universitaire de Québec and Laval University, Quebec City, Canada. jean-mathieu.beauregard@chuq.qc.ca

Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|June 21, 2011
PubMed
Summary

Quantitative SPECT (QSPECT) using Lutetium-177 (177Lu) provides accurate non-invasive imaging. This method enhances diagnostic ability and dosimetry assessment for targeted radionuclide therapy.

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Hybrid &#181;CT-FMT imaging and image analysis
13:45

Hybrid µCT-FMT imaging and image analysis

Published on: June 4, 2015

Related Experiment Videos

Last Updated: May 31, 2026

Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging
08:04

Monitoring Tumor Metastases and Osteolytic Lesions with Bioluminescence and Micro CT Imaging

Published on: April 14, 2011

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Hybrid &#181;CT-FMT imaging and image analysis
13:45

Hybrid µCT-FMT imaging and image analysis

Published on: June 4, 2015

Area of Science:

  • Nuclear Medicine
  • Medical Imaging
  • Radiopharmaceutical Therapy

Background:

  • Accurate quantitative imaging is crucial for dosimetry and therapeutic response assessment in radionuclide therapy.
  • Single Photon Emission Computed Tomography (SPECT)/Computed Tomography (CT) systems offer potential for non-invasive quantitative imaging.
  • Iterative reconstruction algorithms with attenuation and scatter correction are key to improving SPECT accuracy.

Purpose of the Study:

  • To develop and validate a Quantitative SPECT (QSPECT) method for Lutetium-177 (177Lu) using a commercially available SPECT/CT system.
  • To assess the accuracy of the developed QSPECT method in phantom and patient studies.
  • To evaluate the potential of QSPECT for improved dosimetry and therapeutic response assessment.

Main Methods:

  • Serial SPECT/CT scans of 177Lu sources and phantoms were acquired.
  • Iterative reconstruction with attenuation and scatter correction was employed.
  • Camera sensitivity and dead-time were determined to convert SPECT data to QSPECT data (Becquerels per cubic centimetre or SUV).
  • Validation studies were performed using a 177Lu phantom and patients treated with 177Lu-octreotate.

Main Results:

  • The QSPECT method demonstrated high accuracy, with deviations from calibrated activity of 5.6% in phantoms and 2.6% in patients.
  • Camera sensitivity was determined to be 1.08 x 10^-5 s^-1 Bq^-1, with a dead-time constant of 0.78 µs.
  • Patient studies showed dead-time count loss up to 11.7%.

Conclusions:

  • The developed QSPECT method is accurate in phantom models and clinical practice for 177Lu-octreotate therapy.
  • QSPECT offers potential for more accurate dosimetry and therapeutic response assessment compared to planar imaging.
  • Further validation with other radionuclides could expand QSPECT's clinical and research applications.